Xtant™ Medical Reports First Quarter 2016 Results
04. Mai 2016 16:02 ET
|
Xtant Medical Holdings, Inc.
See footnote about the use of pro forma financial information First Quarter 2016 Highlights: Core recurring revenue (excluding OEM and other revenue) increased 6.8% to $20.5 million compared to...
Xtant Medical Holdings, Inc. to Report First Quarter 2016 Financial Results on May 4, 2016
27. April 2016 14:46 ET
|
Xtant Medical Holdings, Inc.
BELGRADE, Mont., April 27, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced...
Xtant Medical Announces Montana Department of Commerce Grant Awards
26. April 2016 06:59 ET
|
Xtant Medical Holdings, Inc.
BELGRADE, Mont., April 26, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced...
Xtant Medical Pre-Announces First Quarter 2016 Revenue
19. April 2016 17:49 ET
|
Xtant Medical Holdings, Inc.
Core recurring revenue to increase 7% to 8% over first quarter 2015The Company reiterates full-year 2016 revenue guidance of $94 million to $99 million and EBITDA guidance of $4.3 million to $6.3...
Xtant Medical Announces FDA Clearance of the Xspan™ Laminoplasty Fixation System
30. März 2016 07:30 ET
|
Xtant Medical Holdings, Inc.
BELGRADE, Mont., March 30, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced...
Xtant Medical Announces Distribution Agreement with Vivex Biomedical Bringing OsteoVive™, a Cellular Allograft, to Market
24. März 2016 09:46 ET
|
Xtant Medical Holdings, Inc.
BELGRADE, Mont., March 24, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a leader in the development of regenerative medicine products and medical devices, is expanding its...
Xtant™ Medical Reports Record $22.3 Million Revenue and 14.1% Growth for the Fourth Quarter 2015
15. März 2016 16:31 ET
|
Xtant Medical Holdings, Inc.
See footnote about the use of pro forma financial information Fourth Quarter 2015 Highlights: Consolidated total revenue increased 14.1% to a record $22.3 million compared to pro forma fourth...
Xtant Medical Holdings, Inc. to Report Fourth Quarter 2015 Financial Results on March 15, 2016
08. März 2016 07:30 ET
|
Xtant Medical Holdings, Inc.
BELGRADE, Mont., March 08, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced...
Xtant™ Medical Receives CE Mark for Its Aranax™ Cervical Plating System and Irix-A™ Stand Alone Anterior Lumbar Interbody Fusion Device
03. März 2016 07:30 ET
|
Xtant Medical Holdings, Inc.
BELGRADE, Mont., March 03, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced...
Xtant™ Medical to Present at the Canaccord Genuity 2016 Musculoskeletal Conference
16. Februar 2016 07:30 ET
|
Xtant Medical Holdings, Inc.
BELGRADE, Mont., Feb. 16, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), formerly Bacterin International Holdings, Inc., a leader in the development of class-leading...